| SCHEDULE OF BASIC AND DILUTED EARNINGS PER SHARE |
The
following table sets forth the computation of basic and diluted earnings per share:
SCHEDULE OF BASIC AND DILUTED EARNINGS PER SHARE
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator for basic earnings per share: | |
| | | |
| | | |
| | | |
| | |
| Net Income (Loss) Attributable to Selectis Health, Inc. | |
$ | 8,123,358 | | |
$ | (308,027 | ) | |
$ | 14,649,740 | | |
$ | (963,996 | ) |
| Series D Preferred Dividends | |
| (7,500 | ) | |
| (7,500 | ) | |
| (15,000 | ) | |
| (22,500 | ) |
| Net Income (Loss) Attributable to Common Stockholders – Basic | |
$ | 8,115,858 | | |
$ | (315,527 | ) | |
$ | 14,634,740 | | |
$ | (986,496 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator for basic earnings per share: | |
| | | |
| | | |
| | | |
| | |
| Weighted Average Common Shares Outstanding - Basic | |
| 3,067,059 | | |
| 3,067,059 | | |
| 3,067,059 | | |
| 3,067,059 | |
| Weighted Average Common Shares Outstanding - Diluted | |
| 3,454,769 | | |
| 3,067,059 | | |
| 3,454,769 | | |
| 3,067,059 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net Income (Loss) per Share Attributable to Common Stockholders: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | 2.65 | | |
$ | (0.10 | ) | |
$ | 4.77 | | |
$ | (0.32 | ) |
| Diluted | |
$ | 2.35 | | |
$ | (0.10 | ) | |
$ | 4.24 | | |
$ | (0.32 | ) |
|
| SCHEDULE OF CONDENSED BALANCE SHEET |
3.
REVISION OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Revision
of Previously Issued Financial Statements
In
connection with the preparation of our condensed consolidated financial statements for the three and six months ended June 30,
2026, the Company’s management identified immaterial errors within our previously issued audited consolidated financial
statements as of and for the year ended December 31, 2025 and the unaudited condensed consolidated financial statements as of and
for the three months ended March 31, 2026. The immaterial errors resulted in: (i) an $0.4 million
overstatement of equity and corresponding $0.4
million understatement of other current liabilities as of December 31, 2025 and March 31, 2026.
The
Company evaluated the materiality of the errors and concluded the errors were not material to the year ended December 31, 2025 and the
three months ended March 31, 2026. Financial information as of December 31, 2025 and for the year ended December 31, 2025 and as of and
for the three months ended March 31, 2026 has been revised in this report to correct the errors. The revisions did not impact previously reported revenue, net income (loss), earnings per share, cash flows, or total
assets. The following table presents a reconciliation
of our unaudited condensed consolidated financial information as originally reported to the revised amounts as of December 31, 2025 and
for the year ended December 31, 2025 and as of and for the three months ended March 31, 2026:
Consolidated
Balance Sheet
SCHEDULE
OF CONDENSED BALANCE SHEET
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
As of December 31, 2025 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Other current liabilities | |
$ | 725,000 | | |
$ | 401,000 | | |
$ | 1,126,000 | |
| Total Liabilities | |
| 38,788,531 | | |
| 401,000 | | |
| 39,189,531 | |
| Series A Preferred Stock | |
| 401,000 | | |
| (401,000 | ) | |
| - | |
| Total Equity (Deficit) | |
| (6,210,538 | ) | |
| (401,000 | ) | |
| (6,611,538 | ) |
Condensed
Consolidated Balance Sheet
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
As of March 31, 2026 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Other current liabilities | |
$ | - | | |
$ | 401,000 | | |
$ | 401,000 | |
| Total Liabilities | |
| 29,753,846 | | |
| 401,000 | | |
| 30,154,846 | |
| Series A Preferred Stock | |
| 401,000 | | |
| (401,000 | ) | |
| - | |
| Total Equity (Deficit) | |
| 258,344 | | |
| (401,000 | ) | |
| (142,656 | ) |
|
| SCHEDULE OF CONDENSED BALANCE SHEET |
SCHEDULE
OF CONDENSED BALANCE SHEET
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
As of December 31, 2025 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Other current liabilities | |
$ | 725,000 | | |
$ | 401,000 | | |
$ | 1,126,000 | |
| Total Liabilities | |
| 38,788,531 | | |
| 401,000 | | |
| 39,189,531 | |
| Series A Preferred Stock | |
| 401,000 | | |
| (401,000 | ) | |
| - | |
| Total Equity (Deficit) | |
| (6,210,538 | ) | |
| (401,000 | ) | |
| (6,611,538 | ) |
Condensed
Consolidated Balance Sheet
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
As of March 31, 2026 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Other current liabilities | |
$ | - | | |
$ | 401,000 | | |
$ | 401,000 | |
| Total Liabilities | |
| 29,753,846 | | |
| 401,000 | | |
| 30,154,846 | |
| Series A Preferred Stock | |
| 401,000 | | |
| (401,000 | ) | |
| - | |
| Total Equity (Deficit) | |
| 258,344 | | |
| (401,000 | ) | |
| (142,656 | ) |
|